Clinical trial NCT06668051: Determination of Functional Exercise Capacity, Respiratory Muscle Endurance in Idiopathic Pulmonary Fibrosis
Official title: Determination of Functional Exercise Capacity, Peripheral Muscle Strength, Respiratory Muscle Endurance and Parameters Affecting Quality of Life in Idiopathic Pulmonary Fibrosis
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Idiopathic Pulmonary Fibrosis
Healthy
Keywords: Quality of life
Muscle strength
Respiratory function tests
Pulmonary fibrosis
Lead sponsor: Hacettepe University
Sponsor class: OTHER
First posted: 2024-10-31
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 12 patients with IPF will be included in the patient group. Twelve healthy individuals, similar in age and gender to the patient group, will be included in the study as a control group.

Brief summary: There are not enough studies in the literature comparing functional capacity, respiratory functions and muscle strength of IPF patients with healthy individuals. This study aims to compare functional capacity, respiratory functions and muscle strength of IPF patients with healthy individuals.


Eligibility criteria: Inclusion Criteria:

* Being over 18 years old
* having a clinical, radiological and/or pathological diagnosis of IPF
* volunteering to participate in the study
* not having had a respiratory tract infection in the last month
* not having an accompanying airway disease such as COPD
* being in the stable phase of the disease

Exclusion Criteria:

* Patients who have had an IPF attack within the last three months and/or are in the acute exacerbation of the disease; who use a walking aid; who have unstable angina or class III-IV heart failure according to the New York Heart Association congestive heart failure classification; who have orthopedic, neuromuscular, neurological and cardiac diseases that may affect walking and balance; who have serious comorbid conditions such as cancer or neoplasm; who have a history of sarcoidosis, tuberculosis, emphysema and/or lung surgery; who have communication problems, mental and cognitive problems, and who cannot adapt to the applied assessment methods will be excluded from the study.

Primary outcomes:
measure: 6 Minute Walk Test (6MWT)
timeFrame: 1 month
measure: 6 Minute Pegboard and Ring Test
timeFrame: 1 month
measure: 30-second sit to stand test
timeFrame: 1 month
measure: Forced Vital Capasity
timeFrame: 1 month
measure: Respiratory Muscle Strength Assessment
timeFrame: 1 month
measure: Respiratory Muscle Endurance Test
timeFrame: 1 month
measure: Hand Grip Strength
timeFrame: 1 month
measure: Quadriceps Strength
timeFrame: 1 month
measure: Respiratory Function Testing
timeFrame: 1 month
measure: Forced expiratory volume in 1 second
timeFrame: 1 month
measure: Forced expiratory flow between 25 and 75% of vital capacity (FEF 25-75)
timeFrame: 1 month
measure: Peak expiratory flow
timeFrame: 1 month
measure: FEV1/FVC
timeFrame: 1 month
Secondary outcomes:
measure: TAMPA KINESOPHOBIA SCALE
timeFrame: 1 month
measure: LEICESTER COUGH QUESTIONNAIRE
timeFrame: 1 month
measure: St. George's Respiratory Questionnaire (SQRQ)
timeFrame: 1 month
measure: Bouchard Three-Day Physical Activity Record
timeFrame: 1 month
Other outcomes:
Locations:
Study officials:
References: